Context Therapeutics Inc (CNTX) Stock Analysis
Verdict: WATCH (do not buy)
Investment score: 44/100
Analysis as of
Is Context Therapeutics Inc stock worth reviewing? The TradeMates thesis
High-risk, pre-revenue biotech with deteriorating earnings quality and significant price volatility.
7-factor investment score
- Valuation: 50/100 (weight 20%)
- Financial Health: 30/100 (weight 15%)
- Technical Momentum: 40/100 (weight 15%)
- Earnings Quality: 25/100 (weight 15%)
- Insider Sentiment: 85/100 (weight 10%)
- Analyst Consensus: 75/100 (weight 10%)
- Risk-Adjusted Return: 35/100 (weight 15%)
Context Therapeutics Inc opportunities and risks
What speaks for CNTX
- Accelerated Clinical Results
What speaks against CNTX
- Cash Runway Risk
Peers and competitors
- PLTH.CN
- PLYX
- CBST.NE
- ANTX
- ORMP
| Ticker | P/E | P/S | EV/EBITDA | Gross margin | Net margin | FCF yield |
|---|---|---|---|---|---|---|
| CNTX | n/a | 0.0x | n/a | 0.0% | 0.0% | -12.3% |
| PLYX | n/a | 0.0x | n/a | 0.0% | 0.0% | -1.6% |
| ANTX | n/a | 0.0x | n/a | 0.0% | 0.0% | -22.7% |
| ORMP | 2.3x | 83.1x | n/a | 0.7% | 3766.2% | -7.9% |
| Peer median | n/a | 0.0x | n/a | 0.0% | 0.0% | -7.9% |
Frequently asked questions about Context Therapeutics Inc (CNTX)
Is CNTX stock a good investment?
The TradeMates model rates Context Therapeutics Inc as WATCH (do not buy) with an investment score of 44/100. High-risk, pre-revenue biotech with deteriorating earnings quality and significant price volatility. This is algorithmic model output, not personal investment advice.
Is CNTX stock a buy?
The TradeMates model verdict for CNTX is WATCH (do not buy) with an investment score of 44/100. Treat this as a model signal to review, not a personal buy recommendation.